Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 484-490

  Wang, Xin ^a   Zhao, Jun ^a   Yang, Lu ^a   Mao, Li ^b   An, Tongtong ^a   Bai, Hua ^a   Wang, Suhang ^a   Liu, Xuyi ^a   Feng, Guoshuang ^a   Wang, Jie ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ERCC1; NSCLC; Platinum based chemotherapy; RRM1

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PROTEIN SUBUNIT; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1 SUBUNIT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77956894860     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9239-3     Document Type: Article

References (25)

1. Parkin DM, Yang L, Li LD, Chen YD. Mortality time trends and the incidence and mortality estimation and projection for lung cancer in China. Chin J Lung Cancer. 2005;4:274-8.
2. Park K. Second-line chemotherapy for advanced non-small cell lung cancer: past, present, and hope for the future. Cancer Res Treat. 2003;35:279-80.
3. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three-platinum-based doublets in advanced nonsmall cell lung cancer. J Clin Oncol. 2002;20:4285-91. doi:10.1200/JCO.2002.02.068. (Pubitemid 35266288)
4. Joan HS, David H, Chandra PB, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8. doi:10.1056/NEJMoa011954. (Pubitemid 34438899)
5. Rosell R, Cecere F, et al. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharm. 2006;6:323-31. doi:10.1016/j.coph.2006.01.011.
6. Crino' L, Foglietta J, Hamzaj A. Lung Cancer. J Thorac Oncol. 2007;2(Suppl 1):24-6.
7. Silvia N, Marina L, et al. Toward Therapies tailored to patient characteristics. J Thorac Oncol. 2007;2(Suppl 1):38-41. doi: 10.1097/01.JTO.0000268642.40826.98. (Pubitemid 47181740)
8. Rosell R, Cuello M, et al. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. Curr Opin Oncol. 2006;18:135-43. doi:10.1097/01.cco.0000208786.91947.eb. (Pubitemid 43740433)
9. Singhal S, Miller D, et al. Gene expression profiling of non-small cell lung cancer. Lung Cancer. 2008;60:313-24. doi:10.1016/j.lungcan.2008.03.007.
10. Shimizu J, et al. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology. 2008;13:510-7. doi:10.1111/j.1440- 1843.2008.01302.x. (Pubitemid 351725293)
11. Wouter L, Nicolaas GJ, Jan HJ. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999;13:768-85. doi:10.1101/gad.13.7.768.
12. Laura JN, Nikhil B, Richard DW. ERCC1 and non-small-cell lung cancer. N Engl J Med. 2007;356:2538-41. doi:10.1056/NEJMc070742.
13. Bepler G, Gautam A, McIntyre LM, et al. Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol. 2002;20:1353-60. doi:10.1200/JCO.20.5.1353. (Pubitemid 34177442)
14. Bepler G, Zheng Z, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer. 2005;47:183-92. doi:10.1016/j.lungcan.2004.07.043. (Pubitemid 40082161)
15. Simon GR, et al. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 2007;39:1318-28. doi:10.1016/j.biocel.2007.05.006. (Pubitemid 47031049)
16. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-91. doi:10.1056/NEJMoa060570. (Pubitemid 44343542)
17. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356:800-8. doi:10.1056/NEJMoa065411. (Pubitemid 46294612)
18. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17:1818-25. doi:10.1093/annonc/mdl300. (Pubitemid 44884058)
19. World Health Organization. Histological typing of lung tumors. In: International histological classification of tumors. Vol. 1, 2nd ed. Geneva: World Health Organization; 1981.
20. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-14. doi:10.1002/1097-0142(19810101)47:1\207::AID- CNCR2820470134[3.0.CO;2-6. (Pubitemid 11167383)
21. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286-91.
22. Georage S, Anupama S, Xueli L, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small cell lung cancer. J Clin Oncol. 2006;25:2741-6.
23. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small-cell lung cancer patients. Clin Cancer Res. 2004;10:1318-25. doi:10.1158/1078-0432.CCR-03-0156. (Pubitemid 38365223)
24. Davidson JD, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004;64:3761-6. doi:10.1158/0008-5472.CAN-03-3363. (Pubitemid 38697284)
25. Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004; 22:1878-85. doi:10.1200/JCO.2004.12.002. (Pubitemid 41095179)